AGE-RELATED MACULAR DEGENERATION

This early-stage study tests a gene therapy called NG101 for wet age-related macular degeneration (AMD), a leading cause of vision loss. About 20 adults aged 50-89 who still need frequent eye injections will receive a one-time shot under the retina. The main goal is to check safe…

This study follows 18 people who already received RetinoStat, a gene therapy for wet age-related macular degeneration, to see if it is safe over the long term. Researchers track side effects and vision changes. The goal is to make sure the treatment remains safe years after a sin…

This early-stage trial tests a gene therapy called KH658 in 9 people with wet age-related macular degeneration (AMD). The treatment delivers a protein that blocks VEGF, the cause of abnormal blood vessel growth, using a harmless virus. The goal is to see if a single injection can…

This study tests whether a pre-filled syringe is as safe as the traditional vial for delivering an eye injection (bevacizumab) to treat wet age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion. About 120 participants will receive the injecti…

This study tests a new treatment called OpRegen for people with advanced dry age-related macular degeneration (geographic atrophy), a leading cause of vision loss. The treatment uses special cells grown from stem cells that are placed under the retina to replace damaged cells. Th…

This early-stage trial tests a gene therapy called KH631 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment delivers a protein that blocks abnormal blood vessel growth, potentially replacing the need for regular eye injection…

This study tests a new system called AVIGA that uses eye-tracking to detect vision problems in people with wet age-related macular degeneration (AMD). Researchers will compare the system's results with standard eye exams to see if it can reliably spot disease activity. The goal i…

This study tests whether AI-assisted software helps eye doctors diagnose four common eye diseases more accurately and quickly. Ten eye doctors and residents will review eye images with and without AI help. The goal is to see if AI improves diagnosis and saves time.

This study follows 110 adults aged 50 and older who previously took part in the AREDS or AREDS2 studies. Researchers will conduct annual eye exams, including vision tests and eye photographs, to monitor the natural progression of age-related macular degeneration and cataracts. Th…